Goodwill and Acquisition-Related Intangibles

9 Months Ended

Sep. 30, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Acquisition-Related Intangibles

Note 16. Goodwill and Acquisition-Related Intangibles

Summaries of goodwill and acquisitions-related intangibles balances as of September 30, 2021 and December 30, 2020 were as follows:

		September 30,			December 31,
	Weighted-Average Amortization Period	2021			2020
		(in thousands)
Goodwill		$	48,749		$	—
Royalty-free technology	10 Years	$	5,706		$	—
Less: accumulated amortization			(238	)		—
Royalty-free technology, net			5,468			—
Customer relationships	12 Years		28,824			—
Less: accumulated amortization			(480	)		—
Customer relationships, net			28,344			—
Trade name	10 Years		1,090			—
Less: accumulated amortization			(19	)		—
Trade name, net			1,071			—
Laboratory information system platform	5 Years		1,860			—
Less: accumulated amortization			(59	)		—
Laboratory information system platform, net			1,801			—
Total acquisition-related intangibles, net		$	36,684		$	—

During the nine months ended September 30, 2021, the Company recorded $23.1 million of goodwill and $7.0 million of intangibles attributable to the FF Gene Biotech Acquisition. See Note 14, Business Combinations, to the Company's condensed consolidated financial statements.

During the three months ended September 30, 2021, the Company recorded $25.7 million of goodwill and $30.5 million of intangibles attributable to the CSI Acquisition. See Note 14, Business Combinations, to the Company's condensed consolidated financial statements.

Based on the carrying value of acquisition-related intangibles recorded as of September 30, 2021, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for acquisition-related intangibles is expected to be as follows:

	Amounts
	(in thousands)
2021 (remaining 3 months)	$	910
2022		3,597
2023		3,597
2024		3,597
2025		3,597
2026		3,278
Thereafter		18,108
Total	$	36,684